Implementing Next-Generation Sequencing Process Changes to Increase Capacity and Improve Timeliness of Molecular Biomarker Profiling for Lung Cancer Patients
Laura Semenuk, Baskoro Kartolo, Harriet E. Feilotter et al. · The Journal of Applied Laboratory Medicine · 2023
BACKGROUND: Faced with expansion of molecular tumor biomarker profiling, the molecular genetics laboratory at Kingston Health Science Centre experienced significant pressures to maintain the provincially mandated 2-week turnaround time (TAT) for lung cancer (LC) patients. We used quality improvement methodology to identify opportunities for improved efficiencies and report the impact of the initiative. METHODS: We set a target of reducing average TAT from accessioning to clinical molecular lab report for LC patients. Process measures included percentage of cases reaching TAT within target and number of cases. We developed a value stream map and used lean methodology to identify baseline inefficiencies. Plan-Do-Study-Act cycles were implemented to streamline, standardize, and automate laboratory workflows. Statistical process control (SPC) charts assessed for significance by special cause variation. RESULTS: A total of 257 LC cases were included (39 baseline January-May 2021; 218 post-expansion of testing June 2021). The average time for baseline TAT was 12.8 days, peaking at 23.4 days after expansion of testing, and improved to 13.9 days following improvement interventions, demonstrating statistical significance by special cause variation (nonrandom variation) on SPC charts. CONCLUSIONS: The implementation of standardized manual and automated laboratory processes improved timeliness of biomarker reporting despite the increasing volume of testing at our center.
Cited by 3 works. doi:10.1093/jalm/jfad105 Open-access PDF
Authors
- Laura Semenuk
- Baskoro Kartolo
- Harriet E. Feilotter
- S. Lee
- Colleen A Savage
- Alexander H. Boag
- Geneviève C. Digby
- Mihaela Mates
References
- The Health Care Data Guide: Learning from Data for Improvement
- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- The landscape and therapeutic relevance of cancer-associated transcript fusions
- Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
- Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care
- Multidisciplinary Care in the Oncology Setting: Historical Perspective and Data From Lung and Gynecology Multidisciplinary Clinics
- Library preparation for next generation sequencing: A review of automation strategies
- Impact of time-to-treatment on overall survival of non-small cell lung cancer patients—an analysis of the national cancer database
- Effectiveness of a thoracic multidisciplinary clinic in the treatment of stage III non-small-cell lung cancer
- Lung Cancer Care Trajectory at a Canadian Centre: An Evaluation of How Wait Times Affect Clinical Outcomes